featured
Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Immunogenicity of ChAdOx1 nCoV-19 Vaccine Administered in a Prime-Boost Regimen in Young and Old Adults (COV002): A Single-Blind, Randomised, Controlled, Phase 2/3 Trial
Lancet 2020 Nov 18;[EPub Ahead of Print], MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, DR Owens, M Voysey, PK Aley, B Angus, G Babbage, S Belij-Rammerstorfer, L Berry, S Bibi, M Bittaye, K Cathie, H Chappell, S Charlton, P Cicconi, EA Clutterbuck, R Colin-Jones, C Dold, KRW Emary, S Fedosyuk, M Fuskova, D Gbesemete, C Green, B Hallis, MM Hou, D Jenkin, CCD Joe, EJ Kelly, S Kerridge, AM Lawrie, A Lelliott, MN Lwin, R Makinson, NG Marchevsky, Y Mujadidi, APS Munro, M Pacurar, E Plested, J Rand, T Rawlinson, S Rhead, H Robinson, AJ Ritchie, AL Ross-Russell, S Saich, N Singh, CC Smith, MD Snape, R Song, R Tarrant, Y Themistocleous, KM Thomas, TL Villafana, SC Warren, MEE Watson, AD Douglas, AVS Hill, T Lambe, SC Gilbert, SN Faust, AJ PollardFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.